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ABSTRACT The RNA helicase DHX33 has been found to be overexpressed in hu-
man cancers, where it promotes cancer development. Previous reports have shown
that DHX33 deficiency caused cancer cell apoptosis, but the underlying mechanism
remains unknown. In this study, we discovered that DHX33 regulates Bcl-2 family
protein expression. In multiple human cancer cell lines, DHX33 was found to stimu-
late the transcription of Bcl-2. Mechanistically, we found that DHX33 interacts with
the AP-2 transcription factor and acts as a coactivator to stimulate Bcl-2 gene tran-
scription. DHX33 deficiency abolished the loading of AP-2 onto the promoter of
Bcl-2 and thereby reduced the recruitment of active RNA polymerase II during tran-
scription initiation. Acute knockdown of DHX33 in multiple human cancer cells
caused decreased Bcl-2 protein level, which ultimately triggered mitochondrion-
mediated cellular apoptosis. In addition, we found that normal human lung and
mammary epithelial cells were less sensitive to acute DHX33 knockdown, implying
that cancer cells are uniquely responsive to DHX33 reduction. These data support
the notion that disruption of DHX33 function could be an important application for
cancer therapy.
KEYWORDS apoptosis, BAD, Bcl-2, Bcl-2 family, DHX33, RNA helicase
The DEAD/DEAH box (DDX/DHX) helicases are involved in multiple aspects of RNAand DNA metabolism, including gene transcription, mRNA splicing/editing, ribo-
some RNA processing, mRNA export, RNA decay, mRNA translation and microRNA-
induced gene silencing (1). They are characterized by their conserved structures that
consist of two tandem domains (RecA1 and RecA2). Eight highly conserved helicase
sequence motifs are arranged along two core domains that are critical for nucleic acid
binding and ATP hydrolysis (2). After substrates bind to the helicase, the two core
domains clench together, and the active ATPase sites are exposed for ATP hydrolysis,
driving the remodeling of DNA/RNA-protein complexes (3). In addition to maintaining
essential cellular processes, DDX/DHX proteins are known to be deregulated in human
cancers (4). Accumulated evidence shows that cancer cells can employ numerous RNA
helicases to promote cancer cell proliferation (5).
DHX33 is a member of the DEAH-box RNA helicase family proteins. We and others
have previously identified DHX33 to be a critical player in cell proliferation and innate
immunity (6–8). It was found to promote ribosome RNA synthesis (7), regulate protein
translation (9), and associate with the promoters of genes involved in cell cycle
regulation (10, 11). DHX33 promotes the recruitment of active RNA polymerase II on
gene promoters to trigger cell cycle progression at all three checkpoints. DHX33 was
additionally found to stimulate the transcription of MMP9, MMP14, and urokinase-type
plasminogen activator (PLAU) to promote cancer cell migration (10). However, it
Citation Wang J, Feng W, Yuan Z, Weber JD,
Zhang Y. 2019. DHX33 interacts with AP-2β to
regulate Bcl-2 gene expression and promote
cancer cell survival. Mol Cell Biol 39:e00017-19.
https://doi.org/10.1128/MCB.00017-19.
Copyright © 2019 American Society for
Microbiology. All Rights Reserved.
Address correspondence to Yandong Zhang,
zhangyd@sustech.edu.cn.
Received 10 January 2019
Returned for modification 2 February 2019
Accepted 29 May 2019





September 2019 Volume 39 Issue 17 e00017-19 mcb.asm.org 1Molecular and Cellular Biology
12 August 2019
 on F











remains unclear whether DHX33 could serve as a coactivator or as a direct transcription
factor to regulate gene expression.
Overexpression of DHX33 was found in several human cancers, such as lung, liver,
lymphoma, and glioblastoma (10–13). Analysis of patients with non-small-cell lung
cancer indicated that DHX33 is highly expressed in 30% (28/95) of cases (11). Elevated
expression of DHX33 was also observed in 66.3% (345/520) of hepatocellular carcinoma
patients, and low DHX33 expression correlated significantly with longer survival time
(12). In human glioblastoma multiforme, DHX33 is highly expressed in 84% (80/95) of
cases analyzed, while 39 cases of normal cerebral tissues were all negative for DHX33
expression (13). Several oncogenic signaling pathways have been found to regulate
DHX33 expression. For instance, DHX33 is a downstream effector of oncogenic RasV12
and is required for RasV12-induced cellular transformation (14). DHX33 expression is also
regulated by c-Myc binding to the DHX33 promoter (10), further underscoring the
integral relationship between DHX33 and known oncogenes.
Bcl-2 family proteins are important regulators of intrinsic apoptosis (15). Diverse
intracellular stress signals act through Bcl-2 family proteins to induce activation of
effector caspases. Bcl-2 family proteins can be divided into two categories, proapop-
totic and antiapoptotic. Sensing intrinsic signals, Bax and Bak homo-oligomerize on the
outer mitochondria membrane to trigger apoptosis through cytochrome c release (16).
BH3-only proteins, such as BIM and PUMA, directly activate BAX, which can be revers-
ibly inhibited by prosurvival proteins, such as Bcl-2, Bcl-xl, and Bcl-w (15, 16). The other
BH3-only protein, BAD, indirectly activates BAK or BAX through competitively inhibiting
Bcl-2 (17). In human cancers, Bcl-2 is frequently overexpressed (18). Although the
relationship of Bcl-2 family members is well characterized, the upstream regulatory
pathway driving the expression of Bcl-2 family proteins remains incompletely under-
stood.
We and others have previously found that knockdown of DHX33 leads to apoptosis
in human cancer cells (8, 11). However, the underlying mechanism of this process
remains obscure. In this study, we reveal that DHX33 represses apoptosis through the
direct upregulation of Bcl-2 gene transcription. We identify that AP-2 is a binding
partner for DHX33 and that DHX33 acts as a coactivator for AP-2 to promote the
transcription of antiapoptotic Bcl-2 gene. In addition, we found that normal human
mammary and lung epithelial cells are less sensitive to DHX33 deficiency, indicating a
unique and heightened sensitivity to DHX33 expression in cancer cells but not normal
cells. Together, our data implicate the therapeutic potential of DHX33 in cancer
treatment.
RESULTS
DHX33 supports breast cancer cell survival. We have previously observed that
lung cancer cells rapidly undergo cell apoptosis after DHX33 knockdown. To investigate
whether DHX33 promotes cell survival in other cancer cell types, we analyzed the effect
of DHX33 knockdown in breast cancer cell lines. We applied several different shRNAs
targeting DHX33 in BT549, HCC1806, and SKBR3 cells, respectively, with shScramble as
a control. As shown in Fig. 1A and D, these shRNAs efficiently reduced DHX33 protein
levels. DHX33 deficiency triggered cell death, as visualized by light microscopy of
enhanced refractive cells (Fig. 1B and E). Through annexin V staining, we determined
that these DHX33-deficient cells underwent apoptosis (Fig. 1C). To evaluate the effect
of DHX33 knockdown in breast cancer cells in vivo, we injected SKBR3 cells that
expressed significantly reduced levels of DHX33 into immunocompromised mice. As
shown in Fig. 1F and G, we found that DHX33 knockdown decreased the tumorigenicity
of SKBR3 cells in vivo. It is clear from these results that DHX33 expression is critical to
support cell survival in breast cancer cells.
The requirement of DHX33 expression in breast cancer cell survival indicates that
DHX33 might be somehow deregulated in breast cancers. To evaluate DHX33 expres-
sion levels in breast cancer cells, we first performed immunoblot analysis by employing
a panel of breast cancer cell lines, with the noncancerous MCF10A cell line as a control.
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As shown in Fig. 2A, we found DHX33 is highly expressed in many breast cancer cell
lines compared to lower expression in MCF10A cells. We further investigated the
expression of DHX33 in breast cancer tissues. As shown in Fig. 2B, the tissue microarray
contains 40 cases of human ductal invasive breast cancer tissues with tumor adjacent
normal tissues for control. The immunohistochemistry scores for cancer tissues are
listed in Table 1. We found that 10 of 40 breast cancer tissues demonstrated highly
positive staining for DHX33, while most tumor adjacent normal tissues displayed
negative DHX33 staining.
DHX33 transcriptionally regulates Bcl-2 family gene expression. To investigate
the underlying mechanism for apoptosis induced by DHX33 reduction, we first ana-
lyzed the changes in total gene expression after DHX33 knockdown. As shown by RNA
sequencing (RNA-seq) results in H1299 lung cancer cells (Fig. 3A), we found that genes
involved in the mitochondrial pathway of apoptosis were highly deregulated. The
mRNA levels of several Bcl-2 family members demonstrated altered expression after
DHX33 knockdown. The Bcl-2 gene itself was significantly downregulated whereas BAD,
FIG 1 DHX33 supports breast cancer cell survival. (A and D) BT549 and HCC1806 (A) or SKBR3 (D) breast cancer cells were transduced with either shSCR or
shRNA-DHX33 lentivirus. At 4 days postinfection, the cells were subjected to Western blot analysis with anti-DHX33 antibody; GAPDH served as an internal
control. (B and E) At 5 days postinfection, images were taken using a phase-contrast microscope. After DHX33 knockdown, obvious cell death was observed.
Typical images are shown at 10 magnification. (C) The cells described above were subjected to apoptosis analysis by flow cytometry using a Vybrant apoptosis
kit after PI labeling of nuclei and FITC labeling of annexin V. Quantitation of apoptotic cells was calculated and graphed. Bars stand for the SD from three
separate analyses. *, P  0.01 (n  3). (F) A group of five nude mice were injected in the flank on one side with SKBR3 cells transduced with either shSCR or
with shDHX33 (106 cells per injection). Tumors were dissected after 3 weeks, and images were obtained before and after tumor removal. (G) Tumors were
weighed; the values in each group were calculated as averages and SD. There is a statistical difference between these two groups.
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BIM, BMF, and PUMA genes were upregulated in H1299 cells after DHX33 knockdown.
To check whether these results also occurred in other cell types, we further performed
reverse transcription-PCR (RT-PCR) analysis for MDA-MB231 cells, BT549 cells, and
MCF10A cells. As shown in Fig. 3B to D, after DHX33 knockdown, Bcl-2 was downregu-
lated, BAD and BIM were upregulated in all three cell lines, whereas BMF, BAK, BOK, and
BAX were upregulated in a cell-type-dependent manner. Interestingly, we observed
that Bcl-xl, Bcl-w, and MCL1 were upregulated in different cell lines after DHX33
knockdown, implicating a possible feedback regulatory mechanism. To confirm the
results from RNA-seq, we further performed immunoblot analysis for both lung cancer
and breast cancer cells (Fig. 4A and B). Depending on the different cell lines, DHX33
knockdown dramatically altered the expression of at least one or multiple Bcl-2 family
members, particularly Bcl-2 gene expression. The altered expression of Bcl-2 family
members caused pre-caspase 7 to be cleaved into caspase 7 (Fig. 4A and B) and PARP
was also cleaved after DHX33 knockdown (Fig. 4A and B). To confirm the expression
changes of Bcl-2 family members at the transcriptional level, RT-PCR analysis was
further performed after DHX33 knockdown. As shown in Fig. 4C, we found that after
DHX33 knockdown, Bcl-2 gene transcription was downregulated in multiple human
cancer cell lines, while the transcript levels of BAD, BIM, and BMF were elevated only in
certain cell types, such as H1299 cells, but not in MDA-MB-231 cells. Deregulation of
these important genes should cause oligomerization of BAX/BAK protein on the outer
membranes of mitochondria, which in turn leads to mitochondrion-mediated apopto-
sis. We therefore analyzed the membrane potential of mitochondria after DHX33
knockdown in cancer cells with JC-1 staining. Under normal conditions, JC-1 will
polymerize in the mitochondria, emitting red fluorescence. However, in apoptotic cells,
due to mitochondrial collapse, JC-1 will stay in the cytosol as monomers to emit green
fluorescence. As shown in Fig. 4D and E, we found that DHX33 knockdown in cancer
FIG 2 Deregulation of DHX33 protein in breast cancer cell lines and tumor tissues. (A) A panel of breast cancer cell
lines was evaluated for the expression of DHX33 protein. These cancer cell lines were ordered in the proliferation
rate, with MCF10A as a control. GAPDH was used as an internal control in Western blot analysis. *, short variant of
DHX33 with a molecular mass of 54 kDa. (B) Immunohistochemistry was performed on a human tissue array,
including 40 cases of invasive ductal carcinoma tissue specimens, with their adjacent normal specimens as controls.
Five representative images of adjacent normal and malignant cancer tissues are shown. All images were obtained
at a 10 magnification.
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cells caused an increase in JC-1 monomers, indicating depolarization of the mitochon-
drial membrane to favor apoptosis.
AP-2 is a binding partner for DHX33 that associates with the promoter of the
Bcl-2 gene. To investigate the underlying molecular mechanism for how DHX33 might
alter Bcl-2 gene transcription, we performed mass spectrometry to identify potential
binding partners for DHX33. We immunoprecipitated DHX33 in two different systems:
one was to immunoprecipitate endogenous DHX33 by anti-DHX33 antibody, and the
other was to immunoprecipitate exogenous FLAG-tagged DHX33 by anti-FLAG anti-
body (both systems used IgG as immunoprecipitation controls). As shown in Table 2,
we found several transcription factors as binding partners for DHX33 from these two
different immunoprecipitation complexes but not in the control IgG samples. Among
these transcription factors, activator protein 2 (AP-2) appeared to be a promising
binding partner for DHX33. We therefore obtained antibodies for AP-2 and AP-2, as
well as for the transcription factors Pur- and Pur-, for further analysis. We initially
used anti-FLAG antibody to immunoprecipitate DHX33 from cell lysates in H1299 and
Calu-1 cells and then performed immunoblot analysis for the identified transcription
factors. As shown in Fig. 5A and B, we found that only AP-2 was confirmed to be a
binding partner for DHX33, while AP-2, Pur-, and Pur- had no interaction with
DHX33 in these cancer cells. The interaction between AP-2 and DHX33 was also
TABLE 1 Clinical data of breast cancer cases and the immunohistochemistry staining
results
Case Staining strength % positive cells Score Pathology diagnosis
1 1 1 2 Invasive lobular carcinoma
2 1 2 3 Invasive lobular carcinoma
3 1 3 4 Medullary carcinoma
4 1 2 3 Invasive ductal carcinoma
5 1 1 2 Invasive ductal carcinoma
6 1 1 2 Invasive ductal carcinoma
7 1 3 4 Invasive ductal carcinoma
8 1 2 3 Invasive ductal carcinoma
9 2 2 4 Invasive ductal carcinoma
10 3 3 6 Invasive ductal carcinoma
11 2 3 5 Invasive ductal carcinoma
12 1 1 2 Invasive ductal carcinoma
13 1 1 2 Invasive ductal carcinoma
14 2 2 4 Invasive ductal carcinoma
15 1 2 3 Invasive ductal carcinoma
16 1 2 3 Invasive ductal carcinoma
17 1 1 2 Invasive ductal carcinoma
18 0 0 0 Invasive ductal carcinoma
19 1 1 2 Invasive ductal carcinoma
20 1 2 3 Invasive ductal carcinoma
21 1 2 3 Invasive ductal carcinoma
22 1 1 2 Invasive ductal carcinoma
23 0 0 0 Invasive ductal carcinoma
24 1 2 3 Invasive ductal carcinoma
25 0 0 0 Invasive ductal carcinoma
26 1 3 4 Invasive ductal carcinoma
27 1 2 3 Invasive ductal carcinoma
28 1 1 2 Invasive ductal carcinoma
29 2 1 3 Invasive ductal carcinoma
30 2 1 3 Invasive ductal carcinoma
31 2 1 3 Invasive ductal carcinoma
32 1 3 4 Invasive ductal carcinoma
33 1 2 3 Invasive ductal carcinoma
34 1 3 4 Invasive ductal carcinoma
35 0 0 0 Invasive ductal carcinoma
36 1 2 3 Invasive ductal carcinoma
37 2 1 3 Invasive ductal carcinoma
38 1 3 4 Invasive ductal carcinoma
39 0 0 0 Invasive ductal carcinoma
40 0 0 0 Invasive ductal carcinoma
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detected in the breast cancer cell line MDA-MB231 and noncancerous MCF10A cells
(Fig. 5C and D). Next, we further performed immunoprecipitation for endogenous
DHX33 in cancer cells with anti-DHX33 antibody. As shown in Fig. 5E, endogenous
DHX33 was found to associate with AP-2. A previous report demonstrated that AP-2
was able to directly repress Bcl-2 gene expression (19). We hypothesized that DHX33
and AP-2 may form a complex that binds to the gene regulatory region of Bcl-2. We
therefore performed chromatin immunoprecipitation (ChIP). As shown in Fig. 5F and G,
we found that the DHX33 protein associated with the promoters of Bcl-2 family
members, including Bcl-2, BAD, BIM, and BMF. Through ChIP analysis, we further
discovered that AP-2 also associated with the promoter of the Bcl-2 gene (Fig. 5H). To
investigate whether DHX33 and AP-2 simultaneously bind to the same Bcl-2 pro-
moter, we further performed (re-chromatin immunoprecipitation (reChIP) analysis, as
shown in Fig. 5I, and we found that DHX33/AP-2 complex can bind to the same Bcl-2
promoter region. These data are consistent with the notion that AP-2 and DHX33 bind
to each other to form a transcriptional regulatory complex for the Bcl-2 gene.
AP-2 and DHX33 cooperate in the regulation of the Bcl-2 gene. To further
understand this AP-2-DHX33 complex, we knocked down AP-2 in lung cancer cells
FIG 3 Bcl-2 family genes were deregulated in DHX33-deficient cells. (A) RNA-seq result from H1299 cells that were transduced with shRNA
or shDHX33 lentivirus. A group of genes were selected for mRNA level comparison; these genes were grouped based on their functions
in the intrinsic apoptosis pathway. (B) MCF10A cells were transduced with either shSCR or shRNA-DHX33 lentiviruses. At 4 days
postinfection, total RNA was extracted and subjected to RT-PCR analysis for Bcl-2 family genes. *, P  0.05 (n  3). (C and D) Breast cancer
cell lines, BT-549 (C) and MDA-MB-231 (D), were transduced with either shSCR or shRNA-DHX33 lentiviruses. At 4 days postinfection, total
RNA was extracted and subjected to RT-PCR analysis for Bcl-2 family genes. *, P  0.05 (n  3).
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FIG 4 DHX33 transcriptionally regulates Bcl-2 family genes. (A and B) The lung cancer cell lines H1299 and Calu-1 or the breast cancer cell lines BT-549 and
MDA-MB-231 were transduced with either shSCR or shRNA-DHX33 lentiviruses. At 4 days postinfection, the cells were subjected to Western blot analysis with
the indicated antibodies for Bcl-2 family members. GAPDH or tubulin was used as an internal control. (C) H1299 lung cancer cells or MDA-MB-231 breast cancer
cells were infected with two different shRNAs targeting DHX33, with shSCR as a control. At 4 days after lentiviral infection, the cells were harvested. Total RNA
was extracted and reverse transcribed into cDNA, and qPCR was performed on these cells with the indicated primers. Bars represent the SD from three
independent analyses. All show statistically significant changes compared to the scramble control. *, P  0.05 (n  3). (D) Calu-1 and BT549 cells were
transduced by lentivirus encoding either shSCR or shDHX33. At 4 days postinfection, the cells were subjected to JC-1 mitochondrial membrane potential
analysis. After JC-1 staining, the cells were analyzed by using a flow cytometer with an excitation wavelength of 488 nm and emission wavelengths of 529 and
590 nm, respectively. Red fluorescence signals represent polymers of JC-1 in mitochondria, while green fluorescence signals represent JC-1 monomers in the
cytosol. (E) Quantitation of the JC-1 polymer/monomer fluorescence ratio after DHX33 knockdown in Calu-1 and BT-549 cells. An increase in JC-1 monomer
indicates mitochondrial depolarization. *, P  0.01 (n  3).
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FIG 5 AP-2 is a binding partner for DHX33 that associates with the promoter of the Bcl-2 gene. (A and B) H1299 (A) or Calu-1 (B) cells were transduced with
lentivirus encoding either empty vector or wild-type FLAG-tagged DHX33. At 4 days postinfection, the cells were subjected to IP analysis with anti-FLAG
antibody; IgG was used as a control. Western blot analysis was performed to analyze each of the indicated proteins. (C and D) MDA-MB231 (C) or MCF10A (D)
cells were transduced with lentivirus encoding either empty vector or wild-type FLAG-tagged DHX33. At 4 days postinfection, the cells were subjected to IP
analysis with anti-FLAG antibody; IgG was used as a control. Western blot analysis was performed to analyze each of the indicated proteins. (E) MDA-MB231
cells were immunoprecipitated with anti-DHX33 antibody (A-3, Santa Cruz Biotech). Immunoprecipitated complexes for endogenous DHX33 were then detected
by Western blot analysis with anti-AP-2 antibody. (F and G) Calu-1 (F) or H1299 (G) cells were subjected to ChIP analysis. Anti-DHX33 antibody was used, with
anti-TATA-binding protein (TBP) as a positive control and IgG as a negative control. Chromatin fragments after IP were then PCR amplified with the designated
primers from BAD and Bcl-2 gene promoters. (H) Calu-1 and H1299 cells were subjected to ChIP analysis. Anti-AP-2 antibody was used, with IgG as a negative
control. Chromatin fragments were then analyzed by PCR with Bcl-2 promoter primers. (I) MDA-MB231 cells were transduced with lentivirus encoding wild-type
DHX33-FLAG. Cells were then subjected to reChIP analysis. The first IP experiment was performed with anti-DHX33 antibody or anti-AP-2 antibody, while the
second IP was performed with the other antibody. It is easy to detect reChIp signal with anti-DHX33 since the first ChIP antibody is followed by anti-AP-2 as
the second antibody.
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and then analyzed cell apoptosis. As shown in Fig. 6A, we designed several shRNAs to
knock down endogenous AP-2 expression. After successfully reducing AP-2 expres-
sion with two different shRNAs, we observed a significant increase in lung cancer cell
apoptosis (Fig. 6B and C). To analyze whether the induction of cell apoptosis could be
through a mitochondrial pathway, we further analyzed the protein levels of Bcl-2 family
genes, including Bcl-2, BAD, and BIM, as shown in Fig. 6A. We found that only Bcl-2 was
significantly downregulated, whereas BAD and BIM had no significant changes at the
protein level. We further found that Bcl-2 transcription was diminished as shown by the
RT-PCR result in Fig. 6D. We did not observe a consistent change of mRNA levels for
BAD and BMF. The mRNA level of BIM had a moderate decrease in AP-2 knockdown
cells. Induction of apoptosis after AP-2 knockdown was observed not only in lung
cancer cells but also in breast cancer cell lines (Fig. 6E and F). However, noncancerous
MCF10A cells appeared to tolerate AP-2 deficiency. We found that AP-2 knockdown
caused the Bcl-2 protein to be downregulated in cancer cell lines, whereas the levels of
BAD and BIM were not influenced. Interestingly, we found that AP-2 knockdown
caused DHX33 protein levels to be markedly increased compared to the control
(Fig. 6A and F). To determine whether there was a reciprocal regulation between AP-2
and DHX33, we further analyzed AP-2 protein levels in DHX33 knockdown cells. As
shown in Fig. 6G, AP-2 level did not undergo marked change after DHX33 knockdown
in H1299 cells, SK-LU1 cells, and Calu-1 cells (Fig. 4A, right panel).
It is likely that DHX33 is required for AP-2 to stimulate Bcl-2 gene transcription. We
therefore performed ChIP in cancer cells after DHX33 knockdown to analyze the
recruitment of AP-2 onto the Bcl-2 gene promoter. As shown in Fig. 6H, we found that
DHX33 deficiency significantly reduced the loading of AP-2 onto the promoter of the
Bcl-2 gene. DHX33 deficiency further reduced the loading of phosphorylated RNA
polymerase II onto the Bcl-2 promoter (Fig. 6I). Moreover, AP-2 knockdown in cancer
cells dramatically reduced the recruitment of activated RNA polymerase II on the Bcl-2
promoter (Fig. 6J), while the loading of DHX33 onto Bcl-2 promoter was enhanced,
possibly due to an increase in the absolute amount of DHX33 protein levels (Fig. 6J).
Expression of DHX33 protects cells from drug-induced apoptosis. In drug-
induced cell apoptosis, proapoptotic proteins, such as PUMA and p53, are significantly
upregulated. During severe DNA damage in cells, we found that DHX33 protein levels
were downregulated, as shown in Fig. 7A. To analyze the effect of wild-type DHX33 in
drug-induced apoptosis, we first expressed DHX33 protein, as shown in Fig. 7B.
Overexpression of DHX33 protein indeed promoted cell survival, as shown in Fig. 7C
and D. We further performed protein expression analysis for cells that were treated with
these drugs after wild-type DHX33 was overexpressed. For comparison, we used the
K94R helicase-defective DHX33 mutant. As shown in Fig. 7E, we found that wild-type
DHX33 lowered the expression of proapoptotic genes, such as BAD and BIM, while the
DHX33 K94R mutant failed to do so. Wild-type DHX33 reduced cancer cell apoptosis
compared to K94R mutant DHX33 (Fig. 7F and G). To check whether DHX33 regulation
of Bcl-2 is dependent on its helicase activity, we analyzed the mRNA levels of Bcl-2 in
H1299 cells. For both vehicle and etoposide treatment samples, we found Bcl-2
upregulation was observed in wild-type DHX33 samples comparing to the helicase-
defective mutant samples (Fig. 7H). This indicates that the helicase activity of DHX33 is
required for gene regulation of Bcl-2.
Normal epithelial cells demonstrate less apoptosis after DHX33 knockdown. To
study the effect of DHX33 deficiency on normal epithelial cells, we first chose MCF10A
cell line for analysis. After infecting MCF10A cells with shRNA lentiviruses targeting
DHX33, MCF10A cells were incubated in fresh medium in the presence of puromycin to
select for the infection-positive cells. Two days after selection, the remaining cells with
puromycin resistance were harvested. Immunoblotting was performed to analyze
protein expression, as shown in Fig. 8A. DHX33 protein levels were decreased with
simultaneous downregulation of Bcl-2. Cyclin B2 served as a control since it has been
shown to be positively regulated by DHX33. To examine the effect of DHX33 depletion
Wang et al. Molecular and Cellular Biology
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FIG 6 AP-2 and DHX33 cooperate in regulation of the Bcl-2 gene. (A) Calu-1 cells were infected by lentivirus encoding either scramble shRNA or shAP-2.
At 4 days postinfection, cell lysates were analyzed by Western blotting with anti-AP-2, anti-DHX33, anti-Bcl-2, anti-BAD, and anti-BIM antibodies. GAPDH
(Continued on next page)
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on cell proliferation and apoptosis of MCF10A cells, DHX33-depleted cells were sub-
jected to fluorescence-activated cell sorting (FACS) analysis for cell cycle distribution
and annexin V-propidium iodide (PI) analysis. Profiles of DHX33-depleted MCF10A cells
are shown in Fig. 8B. We observed cell cycle arrest in these cells after DHX33 knockdown.
However, only a mild increase from 1 to 3% of apoptosis was observed in DHX33-depleted
MCF10A cells compared to the control (Fig. 8B to D). We further performed a similar analysis
using BeaS2B, an immortalized human lung epithelial cell line. As shown in Fig. 8E, DHX33
was successfully knocked down using shRNA lentiviruses. In this cell line, no apparent
changes in BAD and Bcl-2 were observed. Similar to MCF10A cells, DHX33 knockdown
caused BeaS2B cell cycle arrest at the G1/S transition (Fig. 8F), but with no significant
observable cell death (Fig. 8F to H), again underscoring the dramatically different responses
between cancerous and normal cells to DHX33 reduction.
DISCUSSION
In this study, we identified a novel functional complex between AP-2 and DHX33
in Bcl-2 gene regulation and found that DHX33 is a coactivator of AP-2 to stimulate
Bcl-2 gene transcription. Transcription factor AP-2 has been found to play important
roles in embryonic development, cell differentiation, and cell survival (20). The AP-2
protein family includes three different members: AP-2, AP-2, and AP-2 (21–24). All
three AP-2 members share a highly conserved helix-span-helix motif in the C terminus
that is responsible for protein dimerization and DNA binding (25). The sequence of their
DNA-binding domain is unique and does not resemble those from other transcription
factors (26). A palindromic region which is GC-rich has been found to be a preferential
site for AP-2 protein dimer (25). AP-2 DNA transactivation domain contains a proline-
rich region in the amino terminus and an adjacent acidic region. Mechanistically, these
two domains have distinct activity to recruit RNA polymerase II in order to regulate
gene expression (25). The three AP-2 isoforms have different DNA transactivation
sequences and thus different functions in regulating cellular activities (20). This is
supported by the different phenotypes observed in AP-2 and AP-2 gene knockout
mice even though the embryonic expression patterns of AP-2 and AP-2 overlap
significantly (27). Mice deficient for AP-2 develop cranioabdominoschisis and defects
in multiple tissues/organs, while none of this is observed in AP-2-null mice (28, 29).
AP-2 knockout leads to autosomal-recessive polycystic kidney disease due to aberrant
apoptosis after Myc induction (30).
At the level of primary amino acid sequence, AP-2 and AP-2 have 72% sequence
identity and 82% positivity. Their DNA binding domains are exactly the same as shown
in Fig. 9 (31). The core domain of AP-2, which is involved in DNA binding, was found
to be a region spanning amino acid residues 252 to 260. This sequence is identical
between AP-2 and AP-2. They primarily differ by the DNA transactivation domains,
especially in the acidic region. Previous studies have shown that overexpression of
AP-2 caused cell apoptosis through binding to the Bcl-2 promoter to repress its
transcription (19). In the present study, however, we found that AP-2 functions quite
differently in cancer cells. AP-2 promotes the transcription of the Bcl-2 gene through
FIG 6 Legend (Continued)
served as an internal control. (B) The cells mentioned above were further subjected to FACS analysis after PI-annexin V staining. The percentage of cells
in each quadrant is shown. Typical pictures of cell morphology were obtained. (C) Quantitation of apoptotic cells. The percentages of early apoptosis and
late apoptosis were calculated. *, P  0.01 (n  3). (D) For the cells described above, total RNAs were extracted and subjected to quantitative RT-PCR analysis
for expression changes of Bcl-2 family genes. *, P  0.01 (n  3). (E) MCF10A, MDA-MB231, and BT549 cells were separately infected by lentivirus encoding
either scramble shRNA or shAP-2. At 4 days postinfection, the cells were subjected to FACS analysis after PI-annexin V staining. The percentage of the cells
in each quadrant is shown. (F) The cells were subjected to Western blot analysis with the indicated antibodies. GAPDH served as an internal control. (G)
H1299 and SK-LU-1 cells were infected by lentivirus encoding either scramble shRNA or three different shRNAs targeting human DHX33. At 4 days
postinfection, cell lysates were collected and subjected to Western blotting with anti-AP-2 and anti-DHX33 antibodies; GAPDH was used as an internal
control. (H) Calu-1 cells were infected by lentivirus encoding either shSCR or shRNA targeting DHX33. At 4 days postinfection, the cells were subjected to
ChIP analysis with anti-AP-2 antibody, using IgG as a control. Data were plotted against the percentage of input. *, P  0.01 (n  3). (I) For these cells, a
similar ChIP was performed with anti-pPol II antibody, with IgG as a control. Data were plotted against the percentage of input. *, P  0.01 (n  3). (J) Calu-1
cells were infected by lentivirus encoding either shSCR or shRNA targeting AP-2. At 4 days postinfection, the cells were subjected to ChIP analysis with
anti-pPol II and anti-DHX33 antibodies, with IgG as a control. Data were plotted against percentage of input. *, P  0.01 (n  3).
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FIG 7 Expression of DHX33 protects cells from drug-induced apoptosis. (A) SKBR3 cells (left) and H1299 cells (right) were treated with etoposide at different
concentrations for 24 h. Cell lysates were then subjected to Western blotting with the indicated antibodies. (B) H1299 lung cancer cells were infected with
lentivirus encoding either wild-type FLAG-tagged DHX33 or empty vector. At 4 days after lentivirus infection, the cells were analyzed by Western blotting for
the DHX33 protein expression. Tubulin was used as a control. (C) The cells described above were treated with drugs (0.1 M doxorubicin or 10 nM
camptothecin) for 72 h. The supernatant and the adherent cells were collected and stained with FITC-PI. Stained cells were analyzed by flow cytometry. The
percentage of cells is shown in each quadrant. (D) An apoptosis index is displayed in a bar chart. *, P  0.05 (n  3). (E) H1299 cells were further transduced
by lentivirus encoding either empty vector, wild-type DHX33, or a helicase dead mutant DHX33 (K94R). After 72 h, the cells were treated with etoposide (50 M)
or doxorubicin (5 M) for 24 h. Drug-treated cells were further subjected to Western blotting with the indicated antibodies. (F) H1299 cells were transduced
by lentivirus encoding either wild-type DHX33 or helicase dead mutant DHX33 (K94R). After 72 h, the cells were treated with etoposide (50 M) for 24 h;
dimethyl sulfoxide served as a control. The cells were collected and stained with FITC-PI. Stained cells were analyzed by flow cytometry. The percentage of cells
is shown in each quadrant. (G) An apoptosis index is displayed in a bar chart. *, P  0.05 (n  3). (H) Total RNA was extracted from the above-mentioned cells.
The mRNA levels of Bcl-2 were detected by RT-PCR analysis after normalization to a GAPDH control. *, P  0.05 (n  3).
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FIG 8 Normal human epithelia demonstrate less apoptosis after DHX33 knockdown. (A and E) Normal cell lines MCF10A (A) and BEAS-2B
(E) were infected with lentivirus encoding either shSCR or shDHX33. At 4 days postinfection by lentivirus, the protein levels of DHX33,
(Continued on next page)
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direct binding to Bcl-2 gene promoter, thereby recruiting activated RNA polymerase II
to initiate Bcl-2 transcription; this unique AP-2 activity is highly dependent on its
association with DHX33. DHX33 deficiency leads to a reduced loading of AP-2 onto
the promoter of Bcl-2 and therefore reduces the recruitment of RNA polymerase II. Our
results suggest that DHX33 acts as a coactivator of AP-2 in regulating gene expression.
Given that the DNA binding domain is highly conserved between AP-2 and AP-2, it
is possible that these two proteins competitively inhibit each other to regulate Bcl-2
gene transcription, resulting in either cell survival or apoptosis.
AP-2 has been found to be abnormally expressed in multiple human cancers (32,
33). Evidence shows that AP-2 upregulates multiple genes such as MMP-2, MMP-9,
c-Jun, p-ERK, and STAT3 to promote cancer proliferation, migration, and survival (34).
Despite these efforts, AP-2 remains a poorly defined transcription factor. Our study
provides a novel molecular mechanism for the function of AP-2 in cell survival. The
FIG 8 Legend (Continued)
Bcl-2, BAD, and cyclin B2 were analyzed by Western blotting with the indicated antibodies. GAPDH or tubulin was used a control. (B and
F, top rows) For the above-mentioned cells, at 4 days postinfection, the cells were collected and fixed by 75% ethanol. The cells were then
treated with PI. Stained cells were analyzed by flow cytometry for the cell cycle spectrum. (B and F, bottom rows) At 5 days after infection,
the cells were all collected and then stained with FITC-PI. Stained cells were subjected to flow cytometry. The percentage of cells is shown
in each quadrant. (C and G) Quantitation of percentages for G1, S, and G2 phases. (D and H) Quantitation for the apoptosis index.
FIG 9 Sequence alignment between AP-2 and AP-2 and comparison for their structural domains. (A) Structural domains in
AP-2 and AP-2 proteins. The AP-2 transactivation domain is located in the N terminus, specifically including a proline-rich
domain and an acidic domain. The C terminus includes a highly conserved DNA-binding domain and an AP-2 dimerization domain.
(B) Sequence alignment between AP-2 and AP-2 protein sequences. The blue box denotes the DNA-binding region; within this
region, a red box denotes the critical amino acid sequence of AP-2 involved in DNA binding. A green box denotes the AP
dimerization domain.
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function of AP-2 may not be limited to promoting cancer cell survival since DHX33 has
also been shown to be involved in other cellular activities. Therefore, it should be
worthwhile to study whether this novel DHX33-AP-2 functional complex regulates the
expression of other genes. A genomewide analysis should provide more clues regard-
ing the importance of this complex in controlling targeted gene expression.
In this study, we also found that DHX33 protein binds to other gene promoters, such
as BAD, BIM, and BMF genes, even though this appears to occur in a cell-type-
dependent manner. The mechanism for how DHX33 might regulate these genes
remains to be elucidated. It is possible that DHX33 acts as a coactivator or corepressor
through its association with other transcription factors to modulate the expression of
a variety of genes. Regardless, any regulation is likely to require the enzymatic activity
of DHX33, given our findings that a helicase-defective mutant of DHX33 failed to
influence Bad and Bim gene expression. It is interesting that DHX33 was found to bind
to GC-rich regions in both RNA-seq and ChIP-seq analyses (data not shown). It may be
worthwhile to further investigate how the helicase activity of DHX33 is involved in gene
regulation. Genomewide ChIP, coupled with transcriptome analysis, should provide
better clues.
Overall, our study for the first time delineates the novel role of DHX33 in regulating
cancer cell apoptosis. We demonstrated that DHX33 binds to and cooperates with the
AP-2 transcription factor to promote the expression of the prosurvival Bcl-2 gene,
leading to cancer cell survival (Fig. 10). Our data also show that in normal lung and
mammary epithelial cells, DHX33 loss did not cause marked cell death, which contrasts
with the higher sensitivity of cancer cells to DHX33 deficiency. The differential sensi-
tivity to DHX33 loss between normal and cancer cells might be explored as a novel
treatment for human cancers. Since reactivation of apoptosis is a basic principle in
anticancer therapy, it is worthwhile to further explore the effect of DHX33 inhibition in
cancer cells for potential cancer treatment.
MATERIALS AND METHODS
Lentivirus production. To produce lentivirus, pLKO.1-shRNA and virus packaging plasmid pCMV-
VSV-G and pCMVΔR8.2 were transfected into HEK293T cells by Lipofectamine 2000 reagent (Life
Technologies). The shRNA sequences targeting human DHX33 were used previously (9). The shRNA
sequences targeting human AP-2 were (from 5= to 3=) #1-shAP2 (CGGTTCTTTCGAGTTTAGTAA) and
#2-shAP2 (GCGTACAACGGAGCAACAATA). To produce lentivirus overexpressing DHX33, pLVX-FLAG-
tagged wild-type DHX33 or K94R mutant DHX33 and packaging plasmids pCMV-VSV-G with pCMVΔR8.2
FIG 10 Graphic summary. A diagram shows how DHX33 works together with AP-2 to regulate Bcl-2
gene transcription. This causes cancer cell survival, which contributes to tumorigenesis.
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were cotransfected into HEK293T cells. After 48 h, the culture supernatant was collected and centrifuged
at 2,000 rpm for 2 min. Virus was then aliquoted and frozen at – 80°C.
Western blotting and immunoprecipitation. For Western blot analysis, cells were lysed by radio-
immunoprecipitation assay (RIPA) buffer supplemented with protease and phosphatase inhibitors
(Thermo Fisher). After incubation for 10 min on ice, cell lysates were further disrupted by sonication.
Whole-cell extract was then subjected to SDS-PAGE, with a loading amount of 50 g of protein per
sample. Proteins were then transferred onto a polyvinylidene difluoride membrane. Membranes were
blocked in 5% nonfat milk, which was diluted in 1 Tris-buffered saline–Tween (TBST) buffer for 1 h at
room temperature. Primary antibodies diluted in 5% fetal bovine serum (FBS; diluted in 1 TBST) were
incubated with the membrane at 4°C overnight. Membranes were then rinsed with 1 TBST buffer for
multiple times and incubated with horseradish peroxidase-labeled secondary antibodies in 5% FBS
(diluted in 1 TBST) at room temperature for 2 h. Blots were visualized with an ECL kit (Thermo Fisher).
For immunoprecipitation, cells were lysed using EBC cell lysis buffer supplemented with protease and
phosphatase inhibitors (Thermo Fisher). After incubation for 10 min on ice, cell lysates were further
disrupted by sonication. Whole-cell lysates were centrifuged at 13,000 rpm for 10 min at 4°C. Superna-
tants were adjusted to a concentration of approximately 1 mg/ml and incubated with 2 g of indicated
antibody overnight at 4°C; normal IgG was used as a control. The next day, protein A/G-conjugated beads
were added, and cell lysates were further incubated for 1 to 2 h at 4°C. Beads were then washed with EBC
buffer three times before analysis.
The following antibodies were used: anti-DHX33 (A-3 for immunoprecipitation [IP] analysis) and
anti-DHX33 (B-4 for immunohistochemistry and Western blot analysis), Santa Cruz Biotechnology (sc-
390574 and sc-390573); anti-DHX33 for Western blot analysis, Bethyl [A300-800A] and anti-AP-2 (for
Western blot analysis), Cell Signaling Technology (2509S); anti-AP-2 (for IP analysis), ABclonal (A7935);
anti-AP-2, Abcam (ab108311); anti-Pur-, Bethyl (A303-543A-T); anti-Pur-, Bethyl (A303-650A-T); anti-
pPOL II (phosphorylation on S2 for ChIP analysis), Abcam (ab-5095); anti-TBP (for ChIP analysis), Santa
Cruz Biotechnology (sc-204); anti-Bcl-2, Cell Signaling Technology (4223S); anti-BAD, Santa Cruz Biotech-
nology (sc-8044); anti-BIM, Cell Signaling Technology (2933S); anti-PUMA, Abcam (ab33906); anti-GAPDH,
Absin (abs830030); and anti-FLAG (M2) antibody, Sigma (F1840).
Quantitative real-time PCR. The primers were all designed by using the Integrated DNA Technol-
ogies (IDT, Inc., Coralville, IA) online real-time PCR tool and purchased from BGI (Shenzhen). Total RNA
was extracted by using a HighPure RNA isolation kit (Roche) and then transcribed into cDNA by using a
PrimeScript mix kit (TaKaRa). Real-time PCR is performed with an ABI One-Step plus cycler that is
managed with the corresponding software. To analyze mRNA levels, SYBR green Supermix (Bio-Rad) was
used, and transcript quantification was calculated by using the ΔΔCT value after normalization to the
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) values. A melting curve was used to confirm the
amplification of a single product. The primer sequences used for quantitative real-time PCR analyses are
presented in Table 3.
MitoProbe JC-1 assay. Calu-1 cells were infected with lentivirus encoding either scramble shRNA or
shDHX33. At 4 days postinfection, 106 cells were resuspended in 1 ml of warm complete medium and
transferred into 12-well plates. JC-1 was added to a final concentration of 2 M, and cells were incubated
at 37°C with 5% CO2 for 30 min. The cells were then rinsed once with phosphate-buffered saline (PBS)
and resuspended with 500 l of PBS. Finally, cells were analyzed by a flow cytometer with a 488-nm
excitation wavelength and 529-nm/590-nm emission wavelengths. The MitoProbe JC-1 assay kit was
obtained from Thermo Fisher (catalog no. M34152).
Mass spectrometry. Calu-1 cells with or without 3FLAG-tagged DHX33-1 expression were lysed in
EBC buffer (50 mM Tris-HCl, 120 mM NaCl, 1 mM EDTA) containing 1% NP-40, protease-phosphatase
inhibitor cocktail, and 100 U/ml RNase inhibitor). The cells were then incubated on ice for 25 min.
Insoluble material was removed by centrifugation. Equal amounts of lysates were incubated with 4 g
of anti-FLAG antibody (Sigma, F1840) or anti-DHX33 antibody (Bethyl, A300-799A), with IgG as a control.
Magnetic beads were added into a lysate-antibody mixture, followed by incubation for 2 h at 4°C with
rotation. Immunoprecipitates were then washed six times with EBC buffer. Beads were further washed
three times with 50 mM NH4HCO3 before suspension in 50 l of 50 mM NH4HCO3 containing 8 M urea.
Dithiothreitol (DTT) was added to the beads at a final concentration of 10 mM. Samples were incubated
at 30°C for 60 min before the addition of 2 l of 0.5 M iodacetamide at room temperature for 30 min in
the darkness. Then, 350 l of 50 mM NH4HCO3 and 5 l of trypsin/LysC (20:1) were added to the samples
for digestion at 30°C overnight. Formic acid (8 l) was added to the reaction mixture in a new tube, and
the samples were allowed to evaporate for 6 to 8 h. Peptides were desalted by using a ZipTip C18 column
and dried with a SpeedVac. The samples were then submitted for analysis with using liquid chroma-
tography coupled mass spectrometry (Orbitrap Fusion) at the Southern University of Science and
Technology.
Immunohistochemistry. Human breast cancer tissue microarrays were purchased from US Biomax.
This tissue microarray contains 40 cases of lung cancer cases. Tissues were deparaffinized in xylene and
rehydrated in a series of alcohol solution with decreasing concentrations. The antigen was retrieved in
Tris buffer (pH 9.0) in a steamer. Tissues were then incubated in 1% H2O2 in methanol to extinguish
endogenous peroxidase. After being blocked with 10% FBS for 1 h at room temperature, the tissues were
incubated with primary antibody at 4°C overnight. Standard protocol was then followed using a Dako kit
according to the manufacturer’s recommendations. The staining intensity was then scored as follows
based on criteria described previously (35): 0, no staining; 1, weak; 2, moderate; and 3, strong. The
percentages of positively stained cells were rated 1, 2, or 3 if the values were 25%, 25 to 50%, or 50%,
respectively. If the cumulative score was 4, the case was defined as a positive case.
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Chromatin immunoprecipitation. Cells were fixed with 1% formaldehyde at room temperature,
followed by the addition of L-glycine at a final concentration 0.125 M to stop formaldehyde cross-linking.
The cells were then washed with 1 PBS and resuspended in cell lysis buffer (pH 8.1) containing 1% SDS,
10 mM EDTA, and 50 mM Tris supplemented with protease and phosphatase inhibitor cocktails. Cell
lysates were then subjected to extensive sonication to break chromatin. After centrifugation, the cell
lysates are diluted with EBC buffer at a 1:5 ratio. To preclear the cell lysates, samples were incubated with
sheared salmon sperm DNA and protein A/G-beads. Immunoprecipitation was performed by incubation
with 2 g of antibody at 4°C overnight in the presence of sheared salmon sperm DNA. Protein A/G-beads
were then added to the mixture, followed by further incubation for 1 h. The beads were removed by
centrifugation and washed twice with RIPA buffer at 4°C and twice with RIPA buffer containing 500 mM
NaCl at 4°C. For the reChIP experiment, after the first immunoprecipitation and wash, the beads were
incubated with 75 l of the first extraction buffer containing 10 mM Tris-HCl (pH 8.0), 2 mM EDTA, and
10 mM DTT at 37°C for 30 min. After centrifugation, the eluent was then diluted 20-fold with cold EBC
buffer for the second immunoprecipitation. After a wash with cold RIPA buffer for three times, the beads
were then extracted with a solution containing 1% SDS and 0.1 M NaHCO3. The eluted solutions were
combined, and 6 M NaCl was added to a final concentration 0.3 M. To reverse cross-linking, samples were
heated at 65°C for 5 h. After purification of DNA fragments by using a spin column (Qiagen QuickSpin kit),
DNA samples were analyzed by real-time quantitative PCR or by PCRs, followed by agarose gel
electrophoresis. The primer sequences used for ChIP are shown in Table 4.
Fluorescence-activated cell sorter analysis. For cell cycle analysis, cells were trypsinized and
washed with cold PBS. The cells were then fixed by resuspending in 75% ethanol on ice for 30 min. The
cells were then centrifuged and incubated with PBS containing 250 g/ml RNase A and 30 g/ml
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propidium iodide at room temperature for 30 min. Cell samples were subjected to FACS analysis. For
apoptosis analysis, the supernatant (floating apoptotic cells) and the adherent cells were collected and
washed twice with PBS. The cell pellet was then resuspended in binding buffer and stained with FITC-PI
for 15 min at room temperature. Samples were immediately analyzed by FACS.
Mouse xenograft model. Nude female mice were purchased from Beijing Vital River and received
standard institutional care. To prepare cells for nude-mouse injection, SKBR3 cells were infected with
lentivirus containing shDHX33 or scramble as a negative control. The cells were trypsinized and
resuspended with PBS of a final concentration 108 cells/ml. Five-week-old nude mice were subjected to
subcutaneous injection with 107 cells along their flank, with sample sizes of five mice per condition.
When the tumors reached 0.5 cm in diameter, the mice were sacrificed, and the tumors were dissected
for photography.
Statistical analysis. Data are presented as means  the standard deviations (SD). Statistical
significance was determined using the Student t test, with a P value of 0.05 considered significant.
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